Sequence-Enabled Reassembly of β-Lactamase (SEER-LAC): A Sensitive Method for the Detection of Double-Stranded DNA
This work describes the development of a new methodology for the detection of specific double-stranded DNA sequences. We previously showed that two inactive fragments of green fluorescent protein, each coupled to engineered zinc finger DNA-binding proteins, were able to reassemble an active reporter...
Saved in:
Published in | Biochemistry (Easton) Vol. 45; no. 11; pp. 3620 - 3625 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Chemical Society
21.03.2006
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | This work describes the development of a new methodology for the detection of specific double-stranded DNA sequences. We previously showed that two inactive fragments of green fluorescent protein, each coupled to engineered zinc finger DNA-binding proteins, were able to reassemble an active reporter complex in the presence of a predefined DNA sequence. This system, designated sequence-enabled reassembly (SEER), was demonstrated in vitro to produce a DNA-concentration-dependent signal. Here we endow the SEER system with catalytic capability using the reporter enzyme TEM-1 β-lacatamase. This system could distinguish target DNA from nontarget DNA in less than 5 min, representing a more than 1000-fold improvement over our previous SEER design. A single base-pair substitution in the DNA binding sequence reduced the signal to nearly background levels. Substitution of a different custom zinc finger DNA-binding domain produced a signal only on the new cognate target. Signal intensity was not affected by genomic DNA when present in equal mass to the target DNA. These results present SEER as a rapid and sensitive method for the detection of double-stranded DNA sequences. |
---|---|
Bibliography: | ark:/67375/TPS-N9XJ12WQ-9 istex:3477C36CE09E3702088349254B215D9AB09AAA19 D.S. was supported by the American Cancer Society grant IRG7400125 and the NIH grant P50CA95060. C.I.S. was supported by an NIH training grant. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 AUTHOR EMAIL ADDRESSES: segal@pharmacy.arizona.edu, ghosh@email.arizona.edu TO WHOM CORRESPONDENCE SHOULD BE ADDRESSED: David J. Segal, Tel: 530-754-9134, Fax: 530-754-9658, E-mail: djsegal@ucdavis.edu Indraneel Ghosh, Tel: 520-621-6331, E-mail: ghosh@email.arizona.edu PRESENT ADDRESS: Department of Pharmacology/Genome Center University of California, Davis Davis, CA 95616 |
ISSN: | 0006-2960 1520-4995 |
DOI: | 10.1021/bi0517032 |